Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Diego Andrey², Christoph Berger³, Axel Finckh², Pierre Lescuyer², Adrian Ciurea⁴, Tanja Maletic¹, Christos Polysopoulos¹, Myriam Riek¹, Almut Scherer¹, Kim Lauper², Burkhard Moeller⁵, Judith Safford⁶, Sandra Schweizer⁷, Isabell von Loga¹, Nicolas Vuilleumier⁸ and Andrea Rubbert-Roth⁹, ¹SCQM Foundation, Zurich, Switzerland, ²Geneva University Hospital, Geneva, Switzerland, ³University Hospital Basel, Basel, Switzerland, ⁴University Hospital Zurich, Zrich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶RheumaCura Foundation, Zurich, Switzerland, ⁷Swiss League Against Rheumatism, Zurich, Switzerland, ⁸University Hospital of Geneva, Geneva, Switzerland, ⁹Kantonspital St Gallen, St.Gallen, Switzerland
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: L10 • ACR Convergence 2021
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
joshua solomon¹, Felix Woodhead², Sonye Danoff³, Shana Haynes-Harp⁴, Tanvi Naik⁵, Cathie Spino⁵, Shelley Hurwitz⁶, Rie Maurer⁶, Daniel Chambers⁷, Martin Kolb⁸, Hiliary Goldberg⁶ and Ivan Rosas⁴, ¹National Jewish Health, Denver, CO, ²University of Leicester, Leicester, United Kingdom, ³Johns Hopkins University, Baltimore, MD, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Brigham and Womens Hospital, Boston, MA, ⁷University of Queensland, Brisbane, Australia, ⁸McMaster University, Hamilton, ON, Canada
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…
Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
ELVIRA D'ANDREA¹, Rishi Desai², Mengdong He³, Robert Glynn⁴, Hemin Lee², Michael Weinblatt², Daniel Solomon⁵ and Seoyoung Kim², ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
Abstract Number: 166 • 2020 Pediatric Rheumatology Symposium
Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones
Margaret Chang¹, Anais Levescot ², Nathan Nelson-Maney ³, Rachel Blaustein ⁴, Kellen Winden ¹, Allyn Morris ⁴, Spoorthi Balu ⁴, Alexandra Wactor ⁴, Kevin Wei ⁵, Lauren Henderson ⁶, Rachael Clark ⁴, Deepak Rao ⁴, Robert Fuhlbrigge ⁷ and Peter Nigrovic ⁸, ¹Boston Children's Hospital, Boston, ²Boston, ³, ⁴Brigham and Women's Hospital, Boston, ⁵BWH, Boston, ⁶Boston Children's Hospital, Watertown, Massachusetts, ⁷University of Colorado, Aurora, ⁸Boston Children's Hospital, Boston, Massachusetts
Background/Purpose: Resident memory T cells (TRM) are site-specific memory T cells that take up long-term residence in peripheral tissues and aid in pathogen defense. Dysregulated…
Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Evgeniy Nasonov ¹, Saeed Fatenejad ², Elena Korneva ³, Diana Krechikova ⁴, Alexey Maslyansky ⁵, Tatyana Plaksina ⁶, Marina Stanislav ⁷, Rumen Stoilov ⁸, Tamara Tyabut ⁹, Sergey Yakushin ¹⁰, Elena Zonova ¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, Charlotte, North Carolina, ³R-Pharm, Moscow, Russia, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, ⁵SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, ⁶SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁹Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, ¹²Stanford University, Stanford, CA
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
Abstract Number: 2822 • 2019 ACR/ARP Annual Meeting
Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women
Jeffrey Sparks¹, Susan Malspeis ¹, Jill Hahn ², Andrea Roberts ², Laura Kubzansky ² and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard School of Public Health, Boston, MA
Background/Purpose: Depression is associated with elevated systemic inflammation and risk of several chronic diseases including lupus, psoriasis, and inflammatory bowel disease. However, the association between…
Abstract Number: 40 • 2019 ACR/ARP Annual Meeting
Inflammation and Neuronal Growth Factors in Rheumatoid Arthritis
Caroline Wasén¹, Lovisa Leifsdottir ², Roda Abdalla ¹, Lina Juzokaite ¹, Karin Andersson ¹, Malin Erlandsson ¹, Marie Kalm ³ and Maria Bokarewa ¹, ¹Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gotheburg, Sweden, ³hDepartment of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Depression and cognitive impairment are frequently reported in rheumatoid arthritis (RA). We have recently presented that reduced hippocampus volume may be linked to functional…
Abstract Number: 124 • 2019 ACR/ARP Annual Meeting
Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis
Maria-Eugenia Miranda-Carus¹, Paula Fortea-Gordo ², Laura Nuño ³, Alejandro Villalba ⁴, Maria-Jose Santos-Bornez ², Diana Peiteado ², Irene Monjo ¹ and Alejandro Balsa ⁵, ¹FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ²FIBHULP-IdiPAZ-Hospital La Paz, Madrid, Spain, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ⁴FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, ⁵Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain
Background/Purpose: Circulating CD4 T cells that express CXCR5 together with PD-1 and/or ICOS are considered as counterparts of bona fide Tfh cells and function as…
Abstract Number: 208 • 2019 ACR/ARP Annual Meeting
Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)
Patricia Katz¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of California, San Francisco, san francisco, CA, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Sleep disturbances (SD) are reported to be common in RA but relatively few studies have addressed the issue. We examined the frequency and severity…
Abstract Number: 414 • 2019 ACR/ARP Annual Meeting
Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients
Vivek Joseph ¹, Swetha Vontela ², Surjeet Dheer³, Molly Weinberg ⁴, Zuhayr Haq ² and Arundathi Jayatilleke ⁵, ¹Drexel University, PHILADELPHIA, PA, ²Drexel University, Philadelphia, ³Mercy Catholic Medical Center, Philadelphia, ⁴Drexel University, Philadlephia, ⁵Drexel, Philadelphia, PA
Background/Purpose: With the advent of biologic therapy for RA, the American College of Rheumatology advocates a treat to target (TTT) approach in the treatment of…
Abstract Number: 457 • 2019 ACR/ARP Annual Meeting
Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity
Yoko Wada¹, Masanori Sudo ², Daisuke Kobayashi ², Takeshi Kuroda ³ and Masaaki Nakano ⁴, ¹Niigata Rinko Hospital, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ³Health administration office, Niigata University, Niigata, Niigata, Japan, ⁴School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Altered body composition is a common feature of patients with rheumatoid arthritis (RA), up to two-thirds of affected patients showing loss of muscle mass…
Abstract Number: 496 • 2019 ACR/ARP Annual Meeting
Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort
McKayla Muse¹, Ly Tran ¹, Carla J. Guthridge ², Nancy Redinger ² and Judith James ³, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Anti-CCP antibodies are present in the serum of healthy individuals who are at risk of developing RA and serve as an important tool for…
Abstract Number: 540 • 2019 ACR/ARP Annual Meeting
Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar
Lisa Baganz¹, Anja Strangfeld ², Peter Herzer ³, Andreas Krause ⁴, Hans-Peter Tony ⁵ and Angela Zink ⁶, ¹German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center (DRFZ), Berlin, Germany, ³Scientific Advisory Board, München, Germany, ⁴Immanuel Krankenhaus, Berlin, Germany, ⁵Department of Rheumatology/Clinical Immunology, University Hospital, Wuerzburg, Germany, Würzburg, Germany, ⁶German Rheumatism Research Centre and Charité University medicine, Berlin, Germany
Background/Purpose: In Germany, the first etanercept biosimilar was licensed in 2016. In contrast to other European countries there is no uniform recommendation for the prescription…

1
2
3
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].